1. Home
  2. WEN vs COAG Comparison

WEN vs COAG Comparison

Compare WEN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

N/A

Current Price

$7.00

Market Cap

1.5B

ML Signal

N/A

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$41.22

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WEN
COAG
Founded
1969
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2001
2026

Fundamental Metrics

Financial Performance
Metric
WEN
COAG
Price
$7.00
$41.22
Analyst Decision
Hold
Analyst Count
22
0
Target Price
$8.84
N/A
AVG Volume (30 Days)
6.2M
319.9K
Earning Date
05-08-2026
N/A
Dividend Yield
8.28%
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$2,176,891,000.00
N/A
Revenue This Year
$2.26
N/A
Revenue Next Year
$0.94
N/A
P/E Ratio
$24.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$27.47
52 Week High
$10.12
$55.42

Technical Indicators

Market Signals
Indicator
WEN
COAG
Relative Strength Index (RSI) 38.28 38.74
Support Level $7.12 $29.54
Resistance Level $7.28 $51.50
Average True Range (ATR) 0.31 2.96
MACD -0.13 -0.78
Stochastic Oscillator 4.23 16.15

Price Performance

Historical Comparison
WEN
COAG

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: